Source: Fox News
Summary
Neurologists are warning that popular weight-loss medications, such as GLP-1 agonists, may have severe negative effects on neurodegenerative conditions like ALS. According to Dr. Jinsy Andrews, these medications can accelerate physical decline in ALS patients by causing them to lose weight and body fat, which can worsen the disease. Clinical care guidelines for ALS often recommend maintaining or gaining weight to preserve nerve and muscle function. A 2025 case report published in the medical journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration found that a patient’s ALS symptoms worsened significantly after taking semaglutide, a GLP-1 receptor agonist, and improved after discontinuing the medication.
Our Reading
The advice sounds familiar.
Weight-loss medications, like GLP-1 agonists, have been linked to protective effects against obesity, diabetes, and cardiovascular disease. However, for ALS patients, the same medications can have devastating consequences. The clinical rules shift when dealing with neurodegenerative diseases, and what works for one condition may not work for another. Dr. Andrews emphasizes the importance of careful consideration when treating ALS patients with GLP-1 receptor agonists. The case report of the 52-year-old ALS patient who experienced a sudden decline in physical function after taking semaglutide serves as a cautionary tale. As we continue to navigate the complex world of weight-loss medications, it’s clear that one-size-fits-all approaches often fall short.
The recommendation enters another phase, where the benefits of weight loss must be carefully weighed against the risks of accelerating neurodegenerative diseases.
Author: Evan Null
